Strikingly, addition of LOX inhibitor to doxorubicin in these aggressive, fast-growing doxorubicin-resistant tumors led to a significant decrease in tumor growth rate (Fig. 4a, b) and improved survival (Fig. 4c) until experiment termination when the tumor volume cut-off was reached or due to almost a 20% decrease in body weight in BAPN-added treatment arm (Fig. 4d). The gene discussed is LOX; the disease is neoplasm.